) recently entered into a strategic research collaboration
agreement with Oncodesign. Per the terms of the deal, Oncodesign's
Nanocyclix technology will be applied exclusively in several of
Sanofi's kinase target programs for a period of four years.
The deal aims to expedite selection of multiple undisclosed
kinase targets in kinase families. The multiple undisclosed kinase
targets are historically difficult to address.
Sanofi is liable to pay up to €130 million as technology access
fee and on the achievement of discovery, development, regulatory
and commercial milestones along with low single-digit royalties on
Meanwhile, Sanofi received a major boost recently with the
company gaining US approval for Aubagio (teriflunomide), its oral
candidate for relapsing forms of multiple sclerosis (RMS). The US
Food and Drug Administration (FDA) approved Aubagio as a once-daily
treatment for patients with RMS. The approval was based on
encouraging data from a pivotal phase III study (TEMSO) in patients
with RMS. Aubagio is currently under regulatory review in the
Competition in the oral multiple sclerosis market will be
intense and Aubagio needs to demonstrate superior efficacy and
tolerability to gain share.
) Gilenya already has a lead in the oral MS market with the product
being approved in September 2010. Another major competitor could be
's (BIIB) BG-12, which is currently under regulatory review in the
US and the EU.
We currently have a Neutral recommendation on Sanofi. The stock
carries a Zacks #3 Rank (Hold rating) in the short run.
NOVARTIS AG-ADR (NVS): Free Stock Analysis
SANOFI-AVENTIS (SNY): Free Stock Analysis
To read this article on Zacks.com click here.